Jean K Mah

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5170068/publications.pdf

Version: 2024-02-01

66 papers	3,178 citations	186265 28 h-index	161849 54 g-index
69 all docs	69 docs citations	69 times ranked	4072 citing authors

#	Article	IF	Citations
1	Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy. JAMA Network Open, 2022, 5, e2144178.	5.9	31
2	Bi-allelic variants in neuronal cell adhesion molecule cause a neurodevelopmental disorder characterized by developmental delay, hypotonia, neuropathy/spasticity. American Journal of Human Genetics, 2022, 109, 518-532.	6.2	8
3	Routine lung volume recruitment in boys with Duchenne muscular dystrophy: a randomised clinical trial. Thorax, 2022, 77, 805-811.	5.6	8
4	Quantitative magnetic resonance imaging measures as biomarkers of disease progression in boys with Duchenne muscular dystrophy: a phase 2 trial of domagrozumab. Journal of Neurology, 2022, 269, 4421-4435.	3.6	6
5	Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy. JAMA - Journal of the American Medical Association, 2022, 327, 1456.	7.4	43
6	Progressive retinal changes in pediatric multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 61, 103761.	2.0	2
7	<scp>CHRNB1</scp>â€associated congenital myasthenia syndrome: Expanding the clinical spectrum. American Journal of Medical Genetics, Part A, 2021, 185, 827-835.	1.2	6
8	Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study. Neurotherapeutics, 2021, 18, 1127-1136.	4.4	28
9	The clinical course of Duchenne muscular dystrophy in the corticosteroid treatment era: a systematic literature review. Orphanet Journal of Rare Diseases, 2021, 16, 237.	2.7	44
10	Corneal Confocal Microscopy Predicts the Development of Diabetic Neuropathy: A Longitudinal Diagnostic Multinational Consortium Study. Diabetes Care, 2021, 44, 2107-2114.	8.6	28
11	Longitudinally extensive transverse myelitis with positive aquaporin-4 IgG associated with dengue infection: a case report and systematic review of cases. Multiple Sclerosis and Related Disorders, 2021, 55, 103206.	2.0	3
12	Epidemiology, healthcare resource utilization and healthcare costs for spinal muscular atrophy in Alberta, Canada. Journal of Medical Economics, 2021, 24, 51-59.	2.1	7
13	Cost-effectiveness of fingolimod versus interferon-Î²1a for the treatment of pediatric-onset multiple sclerosis in Canada. Journal of Medical Economics, 2020, 23, 1525-1533.	2.1	3
14	Efficacy and safety of vamorolone in Duchenne muscular dystrophy:ÂAn 18-month interim analysis of a non-randomized open-label extension study. PLoS Medicine, 2020, 17, e1003222.	8.4	41
15	Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy. Journal of Comparative Effectiveness Research, 2020, 9, 973-984.	1.4	41
16	Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping. JAMA Neurology, 2020, 77, 982.	9.0	169
17	Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy. Neuromuscular Disorders, 2020, 30, 492-502.	0.6	40
18	The <scp>CINRG</scp> Becker Natural History Study: Baseline characteristics. Muscle and Nerve, 2020, 62, 369-376.	2.2	14

#	Article	IF	Citations
19	Disease-specific and glucocorticoid-responsive serum biomarkers for Duchenne Muscular Dystrophy. Scientific Reports, 2019, 9, 12167.	3.3	35
20	Early corneal nerve fibre damage and increased Langerhans cell density in children with type 1 diabetes mellitus. Scientific Reports, 2019, 9, 8758.	3.3	48
21	Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function. Neurology, 2019, 93, e1312-e1323.	1.1	64
22	A multinational study on motor function in early-onset FSHD. Neurology, 2018, 90, e1333-e1338.	1.1	17
23	Risk factors for non-adherence to disease-modifying therapy in pediatric multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 175-185.	3.0	30
24	An Overview of Recent Therapeutics Advances for Duchenne Muscular Dystrophy. Methods in Molecular Biology, 2018, 1687, 3-17.	0.9	30
25	A Pediatric Review of Facioscapulohumeral Muscular Dystrophy. Journal of Pediatric Neurology, 2018, 16, 222-231.	0.2	15
26	Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet, The, 2018, 391, 451-461.	13.7	306
27	Current Cardiac Imaging Approaches in Duchenne Muscular Dystrophy. Journal of Clinical Neuromuscular Disease, 2018, 20, 85-93.	0.7	8
28	Neuromuscular Ultrasound: A New Tool in Your Toolbox. Canadian Journal of Neurological Sciences, 2018, 45, 504-515.	0.5	36
29	Neuromuscular Ultrasound: Clinical Applications and Diagnostic Values. Canadian Journal of Neurological Sciences, 2018, 45, 605-619.	0.5	35
30	Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug. Pharmacological Research, 2018, 136, 140-150.	7.1	69
31	Current and Emerging Therapies for Duchenne Muscular Dystrophy. Current Treatment Options in Neurology, 2018, 20, 31.	1.8	31
32	Corneal confocal microscopy for identification of diabetic sensorimotor polyneuropathy: a pooled multinational consortium study. Diabetologia, 2018, 61, 1856-1861.	6.3	103
33	Longitudinal Outcomes in the 2014 Acute Flaccid Paralysis Cluster in Canada. Journal of Child Neurology, 2017, 32, 301-307.	1.4	50
34	Impact of an electronic monitoring device and behavioral feedback on adherence to multiple sclerosis therapies in youth: results of a randomized trial. Quality of Life Research, 2017, 26, 2333-2349.	3.1	16
35	Cardiac manifestations of congenital LMNA-related muscular dystrophy in children: three case reports and recommendations for care. Cardiology in the Young, 2017, 27, 1076-1082.	0.8	20
36	Early onset facioscapulohumeral dystrophy â€“ a systematic review using individual patient data. Neuromuscular Disorders, 2017, 27, 1077-1083.	0.6	39

#	Article	IF	Citations
37	Myostatin inhibitor ACEâ€031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placeboâ€controlled clinical trial. Muscle and Nerve, 2017, 55, 458-464.	2.2	176
38	Echocardiographic Image Quality Deteriorates with Age in Children and Young Adults with Duchenne Muscular Dystrophy. Frontiers in Cardiovascular Medicine, 2017, 4, 82.	2.4	19
39	Discovery of Metabolic Biomarkers for Duchenne Muscular Dystrophy within a Natural History Study. PLoS ONE, 2016, 11, e0153461.	2.5	26
40	Cognitive and Behavioral Functioning in Childhood Acquired Demyelinating Syndromes. Journal of the International Neuropsychological Society, 2016, 22, 1050-1060.	1.8	7
41	Facioscapulohumeral dystrophy in children: design of a prospective, observational study on natural history, predictors and clinical impact (iFocus FSHD). BMC Neurology, 2016, 16, 138.	1.8	15
42	Serum pharmacodynamic biomarkers for chronic corticosteroid treatment of children. Scientific Reports, 2016, 6, 31727.	3.3	40
43	Clinical practice considerations in facioscapulohumeral muscular dystrophy Sydney, Australia, 21 September 2015. Neuromuscular Disorders, 2016, 26, 462-471.	0.6	7
44	Polio-Like Illness Associated With Outbreak of Upper Respiratory Tract Infection in Children. Journal of Child Neurology, 2016, 31, 409-414.	1.4	23
45	Bilateral congenital lumbar hernias in a patient with central core disease â€“ A case report. Neuromuscular Disorders, 2016, 26, 56-59.	0.6	5
46	â€œTinkle Tinkle Little Girl, How We Wonder Why You Canâ€™tâ€¦ An Unusual AIDP-like Syndrome in a Toddler. Canadian Journal of Neurological Sciences, 2015, 42, 274-277.	0.5	0
47	The Reliability and Reproducibility of Corneal Confocal Microscopy in Children. , 2015, 56, 5636.		28
48	Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 7153-7158.	7.1	235
49	Unilateral Foot Drop as an Initial Presentation of a Brain Tumor in a Child. Journal of Child Neurology, 2014, 29, 955-958.	1.4	6
50	Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients. Human Molecular Genetics, 2014, 23, 6458-6469.	2.9	106
51	Functionalâ€“structural correlations in the afferent visual pathway in pediatric demyelination. Neurology, 2014, 83, 2147-2152.	1.1	37
52	Validity of the diagnostic criteria for chronic cerebrospinal venous insufficiency and association with multiple sclerosis. Cmaj, 2014, 186, E418-E426.	2.0	12
53	Vibration Therapy Tolerated in Children With Duchenne Muscular Dystrophy: A Pilot Study. Pediatric Neurology, 2014, 51, 126-129.	2.1	19
54	A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. Neuromuscular Disorders, 2014, 24, 482-491.	0.6	350

#	Article	IF	Citations
55	Diabetic neuropathy in children. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 126, 123-143.	1.8	13
56	A Population-Based Study of Dystrophin Mutations in Canada. Canadian Journal of Neurological Sciences, 2011, 38, 465-474.	0.5	41
57	Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurology, The, 2011, 10, 436-445.	10.2	267
58	Being the lifeline: The parent experience of caring for a child with neuromuscular disease on home mechanical ventilation. Neuromuscular Disorders, 2008, 18, 983-988.	0.6	74
59	Parental Stress and Quality of Life in Children With Neuromuscular Disease. Pediatric Neurology, 2008, 39, 102-107.	2.1	54
60	Physician in the movies. Journal of Continuing Education in the Health Professions, 2007, 27, 133.	1.3	1
61	Adolescent quality of life and satisfaction with care. Journal of Adolescent Health, 2006, 38, 607.e1-607.e7.	2.5	44
62	A 10-Year-Old Girl with Progressive Generalized Weakness. Canadian Journal of Neurological Sciences, 2006, 33, 414-417.	0.5	0
63	Comparison of conventional and non-invasive techniques for the early identification of diabetic neuropathy in children and adolescents with type 1 diabetes. Pediatric Diabetes, 2006, 7, 305-310.	2.9	69
64	Parentsâ€™ Global Rating of Mental Health Correlates with SF-36 Scores and Health Services Satisfaction. Quality of Life Research, 2006, 15, 1395-1401.	3.1	15
65	An Infant with Central Nervous System Complications of Disseminated Tuberculosis. Canadian Journal of Neurological Sciences, 2005, 32, 112-114.	0.5	0
66	Sleep disturbances in children with epilepsy compared with their nearestâ€aged siblings. Developmental Medicine and Child Neurology, 2005, 47, 754-759.	2.1	3